⚠️
od kwietnia 2026 zmiany w katalogu chemioterapii: radykalna i paliatywna CTH gruczolakoraka przełyku → docetaksel; 1. L zaawansowanego raka żółądka → paklitaksel
Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bleomycin Sulphate
Capecitabine
Capecitabine (2)
Carboplatin
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxel
Docetaxelum
Doxorubicinum
Epirubicinum
Etoposidum
Fluorouracilum
Ifosfamidum
Imatinibum
Irinotecanum
Lanreotidum
Octreotidum
Oxaliplatinum
Oxaliplatinum (2)
Paclitaxel
Sorafenib
Sunitinib
Temozolomidum
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- gastric cancer
- esophageal cancer
- » A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
- » A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)
- » A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
- » ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- » A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)